|
17.02.2025 10:00:11
|
EQS-News: Sartorius releases Annual Report for 2024
|
EQS-News: SARTORIUS AG
/ Key word(s): Annual Report
Göttingen, Germany | February 17, 2025
Sartorius releases Annual Report for 2024 The life science group Sartorius today released its Annual Report for 2024. The document is available at the following link: https://ir-reports.sartorius.com/en/ag/fy-2024/ Financial calendar March 27, 2025 Annual Shareholders’ Meeting April 16, 2025 Publication of the first quarter results January to March 2025 July 22, 2025 Publication of the half-year results January to June 2025 October 16, 2025 Publication of the nine-month results January to September 2025 A profile of Sartorius Sartorius is a leading international partner of life sciences research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions Division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies safely, rapidly, and sustainably. The company, based in Göttingen, Germany, has a strong global reach with around 60 production and sales sites worldwide. Sartorius regularly expands its portfolio through the acquisition of complementary technologies. In 2024, the company generated sales revenue of around 3.4 billion euros. Around 13,500 employees are working for customers around the globe. Visit our Newsroom and follow Sartorius on LinkedIn. Contact Leona Malorny Head of External Communications +49 551 308 4067 leona.malorny@sartorius.com
17.02.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | SARTORIUS AG |
| Otto-Brenner-Straße 20 | |
| 37079 Göttingen | |
| Germany | |
| Phone: | +49.(0)551-308.0 |
| Fax: | +49.(0)551-308.3289 |
| E-mail: | info@sartorius.com |
| Internet: | www.sartorius.com |
| ISIN: | DE0007165631, DE0007165607 |
| WKN: | 716563, 716560 |
| Indices: | DAX, TecDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard), Hanover; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2086757 |
| End of News | EQS News Service |
|
|
2086757 17.02.2025 CET/CEST
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Sartorius AG Vz.mehr Nachrichten
|
18.02.25 |
Handel in Frankfurt: TecDAX zum Handelsende mit positivem Vorzeichen (finanzen.at) | |
|
18.02.25 |
Pluszeichen in Frankfurt: Zum Handelsende Pluszeichen im LUS-DAX (finanzen.at) | |
|
18.02.25 |
Börse Frankfurt: So entwickelt sich der LUS-DAX nachmittags (finanzen.at) | |
|
18.02.25 |
Dienstagshandel in Frankfurt: DAX am Dienstagnachmittag auf grünem Terrain (finanzen.at) | |
|
18.02.25 |
Starker Wochentag in Frankfurt: TecDAX nachmittags in der Gewinnzone (finanzen.at) | |
|
18.02.25 |
Handel in Frankfurt: TecDAX am Mittag leichter (finanzen.at) | |
|
18.02.25 |
Dienstagshandel in Frankfurt: DAX fällt am Mittag (finanzen.at) | |
|
18.02.25 |
Verluste in Frankfurt: LUS-DAX liegt am Dienstagmittag im Minus (finanzen.at) |
Analysen zu Sartorius AG Vz.mehr Analysen
| 06.02.25 | Sartorius vz. Sector Perform | RBC Capital Markets | |
| 30.01.25 | Sartorius vz. Hold | Warburg Research | |
| 30.01.25 | Sartorius vz. Hold | Deutsche Bank AG | |
| 30.01.25 | Sartorius vz. Neutral | Goldman Sachs Group Inc. | |
| 30.01.25 | Sartorius vz. Hold | Jefferies & Company Inc. |
Aktien in diesem Artikel
| Sartorius AG Vz. | 237,90 | -1,41% |
|
Letzte Top-Ranking Nachrichten
Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.